Lancashire and South Cumbria
Formulary
Formulary
8 Malignant disease and immunosuppression
The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. |
08-01 Drugs for cytotoxic-induced side-effects
| Anhydrous sodium thiosulfate |
|
Formulary
|
For prevention of hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years. |
 NICE TA1034: Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours |
|
| Infliximab |
|
Formulary
|
Treatment of immuno-oncology induced colitis/diarrhoea after failure of steroid treatment. |
 Healthier LSC - Immune-Related Adverse Event: Diarrhoea/Colitis |
|
|
| Vedolizumab Entyvio® |
|
Formulary
|
Treatment of immuno-oncology induced colitis/diarrhoea after failure of steroid treatment. |
|
Healthier LSC - Immune-Related Adverse Event: Diarrhoea/Colitis |
|
|
Links
- Healthier LSC - Immune-Related Adverse Event: Diarrhoea/Colitis
- Healthier LSC - Immune-Related Adverse Event: Diarrhoea/Colitis
- LSC Breast Chemotherapy Protocols
- MHRA Drug Safety Update July 2011: Dexrazoxane (Cardioxane): restriction of use
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug Safety Update July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
- MHRA Drug SAfety Update: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis
- MHRA Drug Safety Update: Panitumumab (Vectibix): risk of necrotising fasciitis
- MHRA Drug Safety Update: Panitumumab (Vectibix): serious hypersensitivity reactions
- NHSE: National Cancer Drugs Fund list
- NICE NG101: Early and locally advanced breast cancer: diagnosis and management
- NICE NG122 : Lung cancer: diagnosis and management
- NICE NG224: Melanoma: assessment and management
- NICE NG47: Haematological cancers: improving outcomes
- NICE NG52: Non-Hodgkin’s lymphoma: diagnosis and management
- NICE NG99: Brain tumours (primary) and brain metastases in adults
- NICE Patient access schemes
- NICE TA1034: Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours
- NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
- NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
- NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
- NICE TA512: Tivozanib for treating advanced renal cell carcinoma